BPC-157 — 22 things I got wrong before I got it right
Thinking out loud about this: BPC-157 — 22 things I got wrong before I got it right.
The three questions, kept separate, because this board runs them together constantly.
Identity: is this the sequence I ordered? Answered by mass spectrometry against a theoretical mass. Quantity: how much peptide is in the vial? Answered by net peptide content, not by area percent. Stability: what happens to it in solution over time? Answered by a stability statement with conditions attached, and almost never asked for.
A certificate that answers one of the three is common. One that answers all three is rare and worth choosing a supplier over. Nothing here is approved for human use in any case, so all three are questions about material rather than about anything else.
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Short peptides in solution are subject to hydrolysis and, depending on sequence, oxidation. Storage state and time in solution are practical variables that this board almost never discusses.
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.
Same. Solution stability is the practical question and almost nobody asks it.
no clinical trial has established what these threads assert
no clinical trial has established what these threads assert
mariam_mensa is right that a pure something-else is still something else.
Agreed. Identity is the question here. A short peptide can be synthesised by almost anyone and the sequence is what you are actually buying.
the human evidence is thin and the rodent evidence is not
What jurisdiction are you asking about? The answer has changed in several.
Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.
regulatory status varies by jurisdiction and it has moved recently
sequence confirmation is the test worth paying for
Yes — the rodent literature is real and it is rodent literature. The gap to a human claim is enormous and it gets crossed in one sentence here.
Push back: "no reported harms" in a literature with almost no human trials is not a safety finding.
most of the claims here trace to the same handful of rodent papers
- 1Agreed. Identity is the question here. A short peptide can be synthesised by…8 comments in this branch · started by u/nils_ferreira